Gyre Therapeutics
GYRE
38 hedge funds and large institutions have $708K invested in Gyre Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 26 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
12% more funds holding
Funds holding: 34 → 38 (+4)
1.4% less ownership
Funds ownership: 2.11% → 0.71% (-1.4%)
73% less capital invested
Capital invested by funds: $2.63M → $708K (-$1.92M)
92% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$65.7K |
| 2 |
HF
HRT Financial
New York
|
+$20.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.8K |
| 4 |
E
Ergoteles
New York
|
+$12.7K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$705K |
| 2 |
Renaissance Technologies
New York
|
-$380K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$181K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$154K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$70.7K |
GYRE Hedge Fund Activity: Q1 2023 in Review
38 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2023, worth a combined $708K — down 73% from $2.63M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GYRE positions and 4 closed out — a net gain of 4 holders — while 2 added to existing stakes and 26 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $65.7K. The largest seller was Vanguard Group, exiting entirely with an estimated $705K sold.
- 38 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2023, up from 34 in Q4 2022.
- Funds reported $708K of Gyre Therapeutics stock for Q1 2023, down 73% quarter-over-quarter.
- 8 funds opened new Gyre Therapeutics positions in Q1 2023 and 4 closed out, a net change of +4 holders.
- The largest Gyre Therapeutics buyer in Q1 2023 was Acadian Asset Management, an estimated $65.7K added.
- The largest Gyre Therapeutics seller in Q1 2023 was Vanguard Group, an estimated $705K sold.
Based on aggregated 13F filings for Q1 2023.